Clin2
NCT07415044Possibly a fitRecruiting

Study of LY4268989 for moderate to severe ulcerative colitis

Ulcerative Colitis (UC)Ulcerative Colitis, Active ModerateUlcerative Colitis, Active Severe

Part of Digestive system clinical trials.

This study tests an investigational medication called LY4268989 for adults with moderate to severe ulcerative colitis (UC). It's for people who have tried other treatments without success. The goal is to see if the drug can reduce inflammation and improve symptoms.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
1,431 people
Ages
18 years to 80 years
Study type
Interventional

Who can take part

  • You must have been diagnosed with ulcerative colitis for at least 3 months.
  • You must have moderate to severe symptoms, including visible inflammation, bleeding, and ulcers on a colonoscopy.
  • You must have tried at least one standard treatment (like steroids or a biologic) that didn't work well enough, stopped working, or caused side effects.
  • You cannot have Crohn's disease, indeterminate colitis, or primary sclerosing cholangitis.
  • You cannot have had cancer (except some skin cancers) in the last 5 years.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06619990Recruiting· Phase 1/Phase 2
Study of XmAb942 for active ulcerative colitis

This study tests a new drug called XmAb942 for people with moderate to severe ulcerative colitis. It aims to see if the drug can reduce inflammation and improve symptoms when other treatments haven't worked well enough or caused side effects.

Scottsdale, Arizona
NCT07507513Recruiting· Phase 2
New drug for moderate to severe ulcerative colitis

This study tests a new medication (called 627) for people with moderate to severe ulcerative colitis who haven't responded well to or couldn't tolerate other treatments. The goal is to see if it can safely reduce inflammation and improve symptoms.

Guangzhou, Guangdong
NCT07744646Not yet recruiting· Phase 1
Study of an experimental tablet for moderate to severe ulcerative colitis

This study tests an experimental tablet for people with moderate to severe ulcerative colitis that hasn't improved with standard treatments. It aims to see if the tablet can reduce symptoms and inflammation.

Hefei, Anhui
NCT06850727Recruiting· Phase 2
Study of OD-07656 then vedolizumab for ulcerative colitis

This trial tests a new drug, OD-07656, followed by vedolizumab, in people with moderate to severe ulcerative colitis. It aims to see if this approach is safe and helps control symptoms when other treatments have not worked well.

Birtinya
NCT07335055Recruiting· Phase 2
Testing HSK47388 for moderate to severe ulcerative colitis

This study tests an experimental drug called HSK47388 for people with moderate to severe ulcerative colitis who have not had good results from other treatments. The goal is to see if it can reduce inflammation and improve symptoms.

Hangzhou
NCT06749795Not yet recruiting· Phase 1
A study of LIV001 for mild-to-moderate ulcerative colitis

This trial tests an investigational drug called LIV001 in people with mild-to-moderate ulcerative colitis. It aims to see if the medicine can help calm inflammation in the colon and improve symptoms.

Wroclaw

Hear when a new Ulcerative Colitis (UC) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.